| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/08/2004 | WO2003074565A3 Peptides for use in antitumor immunotherapy |
| 07/08/2004 | WO2003070192A3 Compositions and methods for surrogate antibody modulation of an immune response and transport |
| 07/08/2004 | WO2003066822A3 Truncated aggrecanase molecules |
| 07/08/2004 | WO2003060145A3 Compositions and methods relating to pancreatic specific genes and proteins |
| 07/08/2004 | WO2003050268A3 Enhancement of the immune response using cd36-binding domain |
| 07/08/2004 | WO2003046204A8 Humanized collagen antibodies and related methods |
| 07/08/2004 | WO2003042358A3 Methods of using 48149, a human aminopeptidase family member |
| 07/08/2004 | WO2003037275A3 Compositions and methods for viral delivery |
| 07/08/2004 | WO2001022916A3 Novel hev antigenic peptide and methods |
| 07/08/2004 | US20040132988 Immunoeffector compounds |
| 07/08/2004 | US20040132983 Comprises nucleotide sequences coding microbial polypeptide for use as diagnostic and therapeutic tools in treatment and prevention of microbial infection |
| 07/08/2004 | US20040132979 Using chromatographic support to isolate and enhance fluid fraction for therapeutic immunoglobulins; vaccines; immunotherapy |
| 07/08/2004 | US20040132974 Cell adhesion polypeptide for use tools in diagnosis, prevention and treatment of cardiovascular, cell proliferative, ischemic, restenotic, blood and gastrointestinal disorders |
| 07/08/2004 | US20040132973 for gene therapy and vaccination; enzyme-linked immunosorbent assay (ELISA); kits; genetic engineering |
| 07/08/2004 | US20040132972 Tri-hybrid melanoma antigen |
| 07/08/2004 | US20040132685 Immunostimulatory nucleic acid |
| 07/08/2004 | US20040132678 Recombinant double-stranded RNA phage, and use of the same |
| 07/08/2004 | US20040132676 Polynucleotide formulation for enhanced intracellular transfer |
| 07/08/2004 | US20040132661 Therapeutic method for treating bone formation diseases |
| 07/08/2004 | US20040132652 Liposome associated to Neisseria meningitis polypeptide fragments or DNA fragments; prevention or diagnosis of infection |
| 07/08/2004 | US20040132178 Postweaning multisystemic wasting syndrome and porcine circovirus from pigs |
| 07/08/2004 | US20040132163 Biological materials and uses thereof |
| 07/08/2004 | US20040132162 Chimeric papillomavirus-like particles |
| 07/08/2004 | US20040132143 using the hyaluronate or chondroitin or heparin/heparosan synthases from Pasteurella, in order to create a variety of glycosaminoglycan oligosaccharides having a natural or chimeric or hybrid sugar structure with a targeted size |
| 07/08/2004 | US20040132140 comprises using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha -bond in a complex N-glycoside-linked sugar chain |
| 07/08/2004 | US20040132139 Comprises nucleotide sequences coding protein with antiproliferative and viricidal activity for use in treatment and prevention of cancer, nervous system, bone and autoimmune disorders |
| 07/08/2004 | US20040132120 Cell regulatory genes, encoded products, and uses related thereto |
| 07/08/2004 | US20040132088 Expression vectors encoding epitopes of target-associated antigens and methods for their design |
| 07/08/2004 | US20040132053 Sphingosine kinase enzyme |
| 07/08/2004 | US20040132038 Membrane protein for use as diagnostic tool in the detection and prevention of cell proliferative, cardiovascular, skin, nervous system, respiratory and metabolic disorders |
| 07/08/2004 | US20040132028 Collection of repeat proteins comprising repeat modules |
| 07/08/2004 | US20040132014 Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits |
| 07/08/2004 | US20040132012 Nucleotide sequences consisiting of DNA viral open reading frames which code proteins which can be used to prepare genetic vaccines which prevent viral diseases |
| 07/08/2004 | US20040132010 Immunogen |
| 07/08/2004 | US20040131650 Mixture containing viral, bacteria, parasitic antigen |
| 07/08/2004 | US20040131643 Immune response potentiation |
| 07/08/2004 | US20040131642 Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof |
| 07/08/2004 | US20040131641 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 07/08/2004 | US20040131640 Escape mutants of newcastle disease virus as marker vaccines |
| 07/08/2004 | US20040131639 Novel recombinant tryptophan mutants of influenza |
| 07/08/2004 | US20040131638 Novel composition |
| 07/08/2004 | US20040131637 Supplying therapeutic protein to patient; vaccine containing microorganisms |
| 07/08/2004 | US20040131634 Neisseria lactoferrin binding protein |
| 07/08/2004 | US20040131633 Induce immunology response; polypeptide |
| 07/08/2004 | US20040131632 Therapeutic formulations containing venom or venom anti-serum either alone or in combination for the therapeutic prophylaxis and therapy of neoplasms |
| 07/08/2004 | US20040131631 Polyphosphazene immunostimulants |
| 07/08/2004 | US20040131630 Administering a attenuated bacteria ; nucleic acids; induce immunology response |
| 07/08/2004 | US20040131629 Viricides: aids therapy |
| 07/08/2004 | US20040131628 Nucleic acids for the treatment of disorders associated with microorganisms |
| 07/08/2004 | US20040131626 Administering a genetic engineered polypeptide |
| 07/08/2004 | US20040131625 Vaccine composition |
| 07/08/2004 | US20040131624 Secreted chlamydia polypeptides and method for identifying such polypeptides by their secretion by a type lll secretion pathway of a gram-negative bacteria. |
| 07/08/2004 | US20040131622 Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids |
| 07/08/2004 | US20040131621 Combinations and kits for treating viral infections using antibodies to aminophospholipids |
| 07/08/2004 | US20040131620 Human polyclonal antibody compositions |
| 07/08/2004 | US20040131619 Thymic atrophy |
| 07/08/2004 | US20040131618 Anticancer agents; diagnosis using alternation of gene expression |
| 07/08/2004 | US20040131616 Methods of inhibiting proliferative diseases |
| 07/08/2004 | US20040131614 Treatment of pulmonary disorders using TNFalpha inhibitor |
| 07/08/2004 | US20040131611 Antitumor agents, anticancer agents; synergistic mixture |
| 07/08/2004 | US20040131610 Antitumor, anticancer agents; complexing phosphatide with antibody, duramycin; prevent reproduction of virus |
| 07/08/2004 | US20040131609 Ultra high affinity neutralizing antibodies |
| 07/08/2004 | US20040131608 Antibodies; suppression, therapy, prevention |
| 07/08/2004 | US20040131599 Fas ligand expressing hematopoietic cells for transplantation |
| 07/08/2004 | US20040131596 Method and compositions for modifying target receptor function associated with neurological disorders |
| 07/08/2004 | US20040131594 Malaria therapy; using pox virus vectors; genetic engineering; antitumor agents |
| 07/08/2004 | US20040131592 Gene expression of alphavirus; nucleotide sequences; induce immunology response; aids vaccine |
| 07/08/2004 | US20040131587 Administering mixture of dendritic cells, apoptosis or necrosis agents,chemattractants |
| 07/08/2004 | US20040131585 Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 07/08/2004 | DE10221411B4 Rekombinantes Fowlpox-Virus Recombinant fowlpox virus |
| 07/08/2004 | CA2511144A1 Ghrelin receptor inverse agonist for regulation of feeding behaviours |
| 07/08/2004 | CA2510787A1 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same |
| 07/08/2004 | CA2510229A1 Production of alvac on avian embryonic stem cells |
| 07/08/2004 | CA2510189A1 Trivalent vaccine with maternal antibody transfer via the milk |
| 07/08/2004 | CA2508273A1 Disease treatment via antimicrobial peptide inhibitors |
| 07/08/2004 | CA2507898A1 Immunoglobulin variants and uses thereof |
| 07/08/2004 | CA2507637A1 Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors |
| 07/07/2004 | EP1435521A1 Detection and diagnosis of transmissible spongiform encephalopathies |
| 07/07/2004 | EP1435232A1 Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 07/07/2004 | EP1434885A2 21132, a human g-protein coupled receptor family member and uses therefor |
| 07/07/2004 | EP1434877A2 Chromogenic in situ hybridization methods, kits, and compositions |
| 07/07/2004 | EP1434862A2 Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies and gene therapy in the cns |
| 07/07/2004 | EP1434860A2 Enzymes |
| 07/07/2004 | EP1434859A2 Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| 07/07/2004 | EP1434858A1 Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| 07/07/2004 | EP1434802A1 Human tissue factor antibodies |
| 07/07/2004 | EP1434801A2 Treatment for central nervous system disorders |
| 07/07/2004 | EP1434799A2 Dna molecules and recombinant dna molecules for producing humanized monoclonal antibodies to s. mutans |
| 07/07/2004 | EP1434794A2 Fragments of heat shock proteins and their use |
| 07/07/2004 | EP1434793A1 RECOMBINANT ALLERGEN WITH REDUCED IgE BINDING BUT UNDIMINISHED T-CELL ANTIGENICITY |
| 07/07/2004 | EP1434788A2 Proteins associated with cell growth, differentiation, and death |
| 07/07/2004 | EP1434785A2 Protein modification and maintenance molecules |
| 07/07/2004 | EP1434778A1 Cytotoxins, prodrugs, linkers and stabilizers useful therefor |
| 07/07/2004 | EP1434775A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 07/07/2004 | EP1434603A2 Method of treatment using ligand-immunogen conjugates |
| 07/07/2004 | EP1434602A2 Cpg formulations and related methods |
| 07/07/2004 | EP1434598A2 Bestrophin and bestrophin homologous proteins involved in the regulation of energy homeostasis |
| 07/07/2004 | EP1434597A1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/07/2004 | EP1434596A1 Enhancement of immune responses by 4-1bb-binding agents |
| 07/07/2004 | EP1434592A1 Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer |